Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) Director Mark Alvino sold 4,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $5.10, for a total value of $20,400.00. Following the transaction, the director now owns 68,334 shares of the company’s stock, valued at $348,503.40. The trade was a 5.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Abeona Therapeutics Stock Performance

Shares of ABEO stock opened at $5.14 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. Abeona Therapeutics Inc has a 52 week low of $3.05 and a 52 week high of $9.01. The company’s 50 day moving average price is $5.80 and its two-hundred day moving average price is $5.72. The company has a market capitalization of $223.44 million, a P/E ratio of -1.91 and a beta of 1.46.

Analyst Ratings Changes

A number of brokerages recently issued reports on ABEO. StockNews.com cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, January 9th. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Monday, November 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th.

Institutional Investors Weigh In On Abeona Therapeutics

Several large investors have recently made changes to their positions in ABEO. Renaissance Technologies LLC boosted its stake in Abeona Therapeutics by 581.6% in the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. abrdn plc lifted its holdings in shares of Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock valued at $2,067,000 after purchasing an additional 200,647 shares in the last quarter. Western Standard LLC boosted its position in shares of Abeona Therapeutics by 7.0% during the third quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock worth $10,732,000 after buying an additional 110,998 shares during the period. Geode Capital Management LLC grew its holdings in shares of Abeona Therapeutics by 21.7% during the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after buying an additional 83,050 shares in the last quarter. Finally, Rosalind Advisors Inc. raised its position in Abeona Therapeutics by 4.7% in the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock valued at $11,578,000 after buying an additional 82,000 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.